WallStSmart

Boston Scientific Corp (BSX)vsLive Nation Entertainment Inc (LYV)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Live Nation Entertainment Inc generates 26% more annual revenue ($25.20B vs $20.07B). BSX leads profitability with a 14.4% profit margin vs 2.0%. BSX appears more attractively valued with a PEG of 0.75. BSX earns a higher WallStSmart Score of 63/100 (C+).

BSX

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 8.7Quality: 5.5
Piotroski: 4/9

LYV

Hold

47

out of 100

Grade: D+

Growth: 5.3Profit: 5.5Value: 4.0Quality: 3.8
Piotroski: 3/9Altman Z: 1.46
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXUndervalued (+1.2%)

Margin of Safety

+1.2%

Fair Value

$70.62

Current Price

$69.78

$0.84 discount

UndervaluedFair: $70.62Overvalued

Intrinsic value data unavailable for LYV.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.3/10
Market CapQuality
$101.28B9/10

Large-cap with strong market position

PEG RatioValuation
0.758/10

Growing faster than its price suggests

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Free Cash FlowQuality
$1.01B8/10

Generating 1.0B in free cash flow

LYV1 strengths · Avg: 10.0/10
Return on EquityProfitability
36.7%10/10

Every $100 of equity generates 37 in profit

Areas to Watch

BSX1 concerns · Avg: 4.0/10
P/E RatioValuation
35.1x4/10

Premium valuation, high expectations priced in

LYV4 concerns · Avg: 2.5/10
Profit MarginProfitability
2.0%3/10

2.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
7.472/10

Expensive relative to growth rate

Price/BookValuation
133.6x2/10

Trading at 133.6x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bull Case : LYV

The strongest argument for LYV centers on Return on Equity. Revenue growth of 11.1% demonstrates continued momentum.

Bear Case : BSX

The primary concerns for BSX are P/E Ratio.

Bear Case : LYV

The primary concerns for LYV are Profit Margin, Piotroski F-Score, PEG Ratio. Thin 2.0% margins leave little buffer for downturns.

Key Dynamics to Monitor

BSX profiles as a growth stock while LYV is a value play — different risk/reward profiles.

LYV carries more volatility with a beta of 1.15 — expect wider price swings.

BSX is growing revenue faster at 15.9% — sustainability is the question.

BSX generates stronger free cash flow (1.0B), providing more financial flexibility.

Bottom Line

BSX scores higher overall (63/100 vs 47/100) and 15.9% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Live Nation Entertainment Inc

COMMUNICATION SERVICES · ENTERTAINMENT · USA

Live Nation Entertainment, Inc is an American global entertainment company, founded in 2010, following the merger of Live Nation and Ticketmaster. The company promotes, operates, and manages ticket sales for live entertainment in the United States and internationally. It also owns and operates entertainment venues, and manages the careers of music artists.

Want to dig deeper into these stocks?